Antibodies, isotypes and complement in allograft rejection

Current Opinion in Organ Transplantation

Volumn 13, Issue 4, 2008, Pages 411-418

  Böhmig, Georg A ^a   Bartel, Gregor ^a   Wahrmann, Markus ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Alloantibody; Complement; Isotype; Rejection; Subclass

Indexed keywords

ANTIBODY; COMPLEMENT COMPONENT C4D; HLA ANTIBODY;

ALLOGRAFT; ALLOIMMUNITY; CELL ASSAY; COMPLEMENT FIXATION; FLOW CYTOMETRY; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; KIDNEY ALLOGRAFT; MAJOR HISTOCOMPATIBILITY COMPLEX; NONHUMAN; REVIEW; SENSITIZATION;

ANIMALS; CAPILLARIES; COMPLEMENT ACTIVATION; COMPLEMENT C4B; COMPLEMENT FIXATION TESTS; DISEASE MODELS, ANIMAL; GRAFT REJECTION; HISTOCOMPATIBILITY; HUMANS; ISOANTIBODIES; ORGAN TRANSPLANTATION; PEPTIDE FRAGMENTS; TRANSPLANTATION TOLERANCE; TRANSPLANTATION, HOMOLOGOUS;

EID: 62549110546     PISSN: 10872418     EISSN: 15317013     Source Type: Journal    
DOI: 10.1097/MOT.0b013e3283028312     Document Type: Review

References (56)

1. Patel R, Terasaki PI. Significance of the positive crossmatch test in kidney transplantation. N Engl J Med 1969; 280:735-739.
2. Racusen LC, Colvin RB, Solez K, et al. Antibody-mediated rejection criteria -an addition to the Banff 97 classification of renal allograft rejection. Am J Transplant 2003; 3:708-714.
3. Pei R, Lee JH, Shih NJ, et al. Single human leukocyte antigen flow cytometry beads for accurate identification of human leukocyte antigen antibody specificities. Transplantation 2003; 75:43-49.
4. Zou Y, Stastny P,SüsalC, et al. Antibodies against MICA antigens and kidneytransplant rejection. N Engl J Med 2007; 357:1293-1300.
5. Lee PC, Terasaki PI,TakemotoSK, et al. All chronic rejection failures of kidney transplants were preceded by the development of HLA antibodies. Transplantation 2002; 74:1192-1194.
6. Ozawa M, Terasaki PI, Lee JH, et al. 14th International HLA and Immunogenetics Workshop: report on the Prospective Chronic Rejection Project. Tissue Antigens 2007; 69 (Suppl 1):174-179.
7. Cecka JM, Zhang Q, Reed EF. Preformed cytotoxic antibodies in potential allograft recipients: recent data. Hum Immunol 2005; 66:343-349.
8. Cecka JM. Does flow cytometry crossmatch predict renal allograft outcome in patients with a negative antiglobulin crossmatch? Nat Clin Pract Nephrol 2007; 3:136-137.
9. Wasowska BA, Lee CY, Halushka MK, Baldwin WM III. New concepts of complement in allorecognition and graft rejection. Cell Immunol 2007; 248: 18-30.
10. Feucht HE, Schneeberger H, Hillebrand G, et al. Capillary deposition of C4d complement fragment and early renal graft loss. Kidney Int 1993; 43:1333-1338.
11. Reed EF, Demetris AJ, Hammond E, et al. Acute antibody-mediated rejection of cardiac transplants. J Heart Lung Transplant 2006; 25:153-159.
12. Solez K, Colvin RB, Racusen LC, et al. Banff '05 Meeting Report: differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy ('CAN'). Am J Transplant 2007; 7:518-526.
13. Mauiyyedi S, Crespo M, Collins AB, et al. Acute humoral rejection in kidney transplantation. II: Morphology, immunopathology, and pathologic classification. J Am Soc Nephrol 2002; 13:779-787.
14. Bohmig GA, Exner M, Habicht A, et al. Capillary C4d deposition in kidney allografts: a specific marker of alloantibody-dependent graft injury. J Am Soc Nephrol 2002; 13:1091 -1099.
15. Scornik JC, Guerra G, Schold JD, et al. Value of posttransplant antibody tests in the evaluation of patients with renal graft dysfunction. Am J Transplant 2007; 7:1 808-1814.
16. Worthington JE, McEwen A, McWilliam LJ, et al. Association between C4d staining in renal transplant biopsies, production of donor-specific HLA antibodies, and graft outcome. Transplantation 2007; 83:398-403.
17. Bocrie O, Hussein Aly AA, Guignier F, et al. Distribution of donor-specific antibodies in the cortex and the medulla of renal transplants with chronic allograft nephropathy. Transpl Immunol 2007; 17:227-229.
18. NadasdyGM, Bott C, Cowden D, et al. Comparative study for the detection of peritubular capillary C4d deposition in human renal allografts using different methodologies. Hum Pathol 2005; 36:1178-1185.
19. Bartel G, Wahrmann M, Exner M, et al. In vitro detection of C4d-fixing HLA alloantibodies: associations with capillary C4d deposition in kidney allografts. Am J Transplant 2008; 8:41 -49.
20. Uehara S, Chase CM, Cornell LD, et al. Chronic cardiac transplant arteriopathy in mice: relationship of alloantibody, C4d deposition and neointimal fibrosis. Am J Transplant 2007; 7:57-65.
21. Minami K, Murata K, Lee C-Y, et al. C4d deposition and clearance in cardiac transplants correlates with alloantibody levels and rejection in rats. Am J Transplant 2006; 6:923-932.
22. Qian Z, Lee CY, Murata K, et al. Antibody and complement mediated injury in transplants following sensitization by allogeneic blood transfusion. Transplantation 2006; 82:857-864.
23. Murata K, Fox-Talbot K, Qian Z, et al. Synergistic deposition of C4d by complement-activating and nonactivating antibodies in cardiac transplants. Am J Transplant 2007; 7:2605-2614.
24. Lederer SR, Schneeberger H, Albert E, et al. Early renal graft dysfunction. The role of preformed antibodies to DR-typed lymphoblastoid cell lines. Transplantation 1996; 61:313-319.
25. Wahrmann M, Exner M, Regele H, et al. Flow cytometry based detection of HLA alloantibody mediated classical complement activation. J Immunol Methods 2003; 275:149-160.
26. KushihataF, Watanabe J, Mulder A, et al. Human leukocyte antigen antibodies and human complement activation: role of IgG subclass, specificity, and cytotoxic potential. Transplantation 2004; 78:995-1001.
27. Smith JD, Hamour IM, Banner NR, Rose ML. C4d fixing, luminex binding antibodies - a new tool for prediction of graft failure after heart transplantation. Am J Transplant 2007; 7:2809-2815.
28. Terasaki PI, McClelland JD. Microdroplet assay of human serum cytotoxins. Nature 1964; 204:998-1000.
29. Schonemann C, Lachmann N, Kiesewetter H, Salama A. Flow cytometric detection of complement-activating HLA antibodies. Cytometry B Clin Cytom 2004; 62:39-45.
30. Won DI, Jeong HD, Kim YL, Suh JS. Simultaneous detection of antibody binding and cytotoxicity in flow cytometry crossmatch for renal transplantation. Cytometry B Clin Cytom 2006; 70:82-90.
31. Watanabe J, Scornik JC. Measuring human complement activation by HLA antibodies. Arch Pathol Lab Med 2006; 130:368-373.
32. Wahrmann M, Exner M, Haidbauer B, et al. [C4d]FlowPRA screening - a specific assay for selective detection of complement-activating anti-HLA alloantibodies. Hum Immunol 2005; 66:526-534.
33. Wahrmann M, Exner M, Schillinger M, et al. Pivotal role of complement-fixing HLA alloantibodies in presensitized kidney allograft recipients. Am J Transplant 2006; 6:1033-1041.
34. Le Bas-Bernardet S, Hourmant M, Valentin N, et al. Identification of the antibodies involved in B-cell crossmatch positivity in renal transplantation. Transplantation 2003; 75:477-482.
35. Bindon CI, Hale G, Bruggemann M, Waldmann H. Human monoclonal IgG isotypes differ in complement activating function at the level of C4 as well as C1q. J Exp Med 1988; 168:127-142.
36. Bartel G, Wahrmann M, Exner M, et al. Determinants of the complement-fixing ability of recipient presensitization against HLA antigens. Transplantation 2007; 83:727-733.
37. Griffiths EJ, Nelson RE, Dupont PJ, Warrens AN. Skewing of pretransplant anti-HLA class I antibodies of immunoglobulin G isotype solely toward immunoglobulin G1 subclass is associated with poorer renal allograft survival. Transplantation 2004; 77:1771 -1773.
38. Kerman RH, Susskind B, Buelow R, et al. Correlation of ELISA-detected IgG and IgA anti-HLA antibodies in pretransplant sera with renal allograft rejection. Transplantation 1996; 62:201-205.
39. Monteiro F, Mineiro C, Rodrigues H, et al. Pretransplant and posttransplant monitoring of anti-HLA class I IgG1 antibodies by ELISA identifies patients at high risk of graft loss. Transplant Proc 1997; 29:1433-1434.
40. GaoZH,McAlisterVC,WrightJRJr,et al.Immunoglobulin- Gsubclassantidonor reactivity in transplant recipients. Liver Transpl 2004; 10:1055-1059.
41. Karuppan SS, Ohlman S, Moller E. The occurrence of cytotoxic and non-complement-fixing antibodies in the crossmatch serum of patients with early acute rejection episodes. Transplantation 1992; 54:839-844.
42. Arnold ML, Zacher T, Dechant M, et al. Detection and specification of noncomplement binding anti-HLA alloantibodies. Hum Immunol 2004; 65:1288-1296.
43. Worthington JE, Thomas AA, Dyer PA, Martin S. Detection of HLA-specific antibodies by PRA-STAT and their association with transplant outcome. Transplantation 1998; 65:121-125.
44. Khan N, Robson AJ, Worthington JE, Martin S. The detection and definition of IgM alloantibodies in the presence of IgM autoantibodies using flowPRA beads. Hum Immunol 2003; 64:593-599.
45. Chapman JR, Taylor CJ, Ting A, Morris PJ. Immunoglobulin class and specificity of antibodies causing positive T cell crossmatches. Relationship to renal transplant outcome. Transplantation 1986; 42:608-613.
46. McCalmon RT Jr, Tardif GN, Sheehan MA, et al. IgM antibodies in renal transplantation. Clin Transplant 1997; 11:558-564.
47. Koka P, Chia D, Terasaki PI, et al. The role of IgA anti-HLA class I antibodies in kidney transplant survival. Transplantation 1993; 56:207-211.
48. Doran TJ, Süsal C, Opelz G, Geczy AF. IgA class antibodies and flow cytometric cross-matching in renal transplantation. Transplantation 1999; 67:309-314.
49. Groth J, Schonemann C, Kaden J, May G. Dynamics of donor-reactive IgG, IgAand IgM antibodies againstT and B lymphocytes early after clinical kidney transplantation using flow cytometry. Transpl Immunol 1996; 4:215-219.
50. Lietz K, John R, Burke E, et al. Immunoglobulin M-to-immunoglobulin G antihuman leukocyte antigen class II antibody switching in cardiac transplant recipients is associated with an increased risk of cellular rejection and coronary artery disease. Circulation 2005; 112:2468-2476.
51. Bindon CI, Hale G, Waldmann H. Importance of antigen specificity for complement-mediated lysis by monoclonal antibodies. Eur J Immunol 1988; 18:1507-1514.
52. Martin L, Guignier F, Mousson C, et al. Detection of donor-specific anti-HLA antibodies with flow cytometry in eluates and sera from renal transplant recipients with chronic allograft nephropathy. Transplantation 2003; 76: 395-400.
53. AdeyiOA, GirnitaAL, Howe J, et al. Serum analysis after transplant nephrectomy reveals restricted antibody specificity patterns against structurally defined HLA class I mismatches. Transpl Immunol 2005; 14:53-62.
54. Mizutani K, Terasaki P, Hamdani E, et al. The importance of anti-HLA-specific antibody strength in monitoring kidney transplant patients. Am J Transplant 2007; 7:1027-1031.
55. Lefaucheur C, Suberbielle-Boissel C, Hill GS, et al. Clinical relevance of preformed HLA donor-specific antibodies in kidney transplantation. Am J Transplant 2008; 8:324-331.
56. Schaub S, Scornik JC. High-tech detection of HLA antibodies and complement: prospects and limitations. Am J Transplant 2008; 8:5-6.